Dr. Rémi Rabasa-Lhoret
Claim this profileInstitut de recherches cliniques de Montréal
Affiliated Hospitals
Institut De Recherches Cliniques De Montréal
Montreal Clinical Research Institute
Clinical Trials Rémi Rabasa-Lhoret is currently running
Continuous Glucose Monitoring
for Cystic Fibrosis
Cystic fibrosis (CF)-related diabetes (CFRD) is the most important emerging complication after pulmonary complications. This specific form of diabetes is associated with an increased morbidity and mortality. CFRD prevalence at the age of 10 is 10% and reaches 40 to 50% in adulthood, while a similar percentage is afflicted with milder dysglycemia also called pre-diabetes abnormalities. In order to identify patients at risk and to implement early therapeutic measures, an annual CFRD screening test is recommended for CF patients after 10 years of age. The standard 2-hour oral glucose tolerance test (OGTT) is the recommended screening test. However, this test is perceived by both patients and CF care teams as unpleasant while adding a significant burden and workload, resulting in screening rates lower than 50% in most centers. An ideal alternative test should be simpler, less invasive, more sensitive than an OGTT to establish risks for lung function and/or nutritional deterioration, and predict future CFRD risk. To date, compared to the OGTT, no alternative screening method has demonstrated its effectiveness. However, continuous glucose monitoring (CGM) is emerging as a possible alternative method. In patients living with CF, CGM is easy to use and can identify early dysglycemia, which in turn, can predict increased risk of accelerated decline of pulmonary function and/or weight, higher risk of pseudomonas colonization, and future risk of CFRD. However, these observations are based on studies of small sample size with very limited prospective data. Furthermore, many of the multiple CGM metrics that have been standardized are based on the risk of complications associated with Type 1 and Type 2 Diabetes. Thus, there is a need for prospective studies to identify the CGM metrics and the cut-off level that is relevant as a predictor of clinical deterioration and/or CFRD risk in CF. The identification of such CF-specific criteria would provide important information to target at-risk patients.
Recruiting
1 award
N/A
3 criteria
Exercise Blood Glucose Management
for Type 1 Diabetes
Despite major technological advances in type 1 diabetes (artificial pancreas), the management of hypoglycemia remains a major challenge, especially during and after physical activity. The primary outcome is to determine the temporary blood glucose (BG) target to be set 60 minutes before aerobic exercise in people with type 1 diabetes (PWT1D) using do-it-yourself automated insulin delivery (DIY-AID) systems. Three glycemic thresholds to be applied 60 minutes before physical activity will be tested in 32 people on AID-DIY: 8.3 (current target for commercial AID systems), 8.8, and 9.3 mmol/L. Each participant will perform 3 sessions of moderate aerobic physical activity (ergocycle) at 60% of vo2peak with a different glycemic target each time (random order). Plasma glucose will be measured every 20 minutes before and during physical activity, and blood glucose measured by continuous glucose reading (DEXCOM) for 24 hours post-intervention. Once the best glycemic target is selected, participants could come to the research center for 1 or 2 more voluntary interventions to test the threshold during 1) fasting exercise and 2) late luteal phase of the menstrual cycle.
Recruiting
1 award
N/A
7 criteria
More about Rémi Rabasa-Lhoret
Clinical Trial Related
6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Rémi Rabasa-Lhoret has experience with
- Insulin
- Home-based High Intensity Interval Training
- Physical Activity Trial Intervention
- Single-hormone Closed-loop System
- Continuous Glucose Monitoring System
- Aspart Or Lispro
Breakdown of trials Rémi Rabasa-Lhoret has run
Type 1 Diabetes
Diabetes
Hypoglycemia
Motor Skills
Low blood sugar awareness
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rémi Rabasa-Lhoret specialize in?
Rémi Rabasa-Lhoret focuses on Type 1 Diabetes and Diabetes. In particular, much of their work with Type 1 Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Rémi Rabasa-Lhoret currently recruiting for clinical trials?
Yes, Rémi Rabasa-Lhoret is currently recruiting for 2 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Rémi Rabasa-Lhoret has studied deeply?
Yes, Rémi Rabasa-Lhoret has studied treatments such as Insulin, Home-based High Intensity Interval Training, Physical activity trial intervention.
What is the best way to schedule an appointment with Rémi Rabasa-Lhoret?
Apply for one of the trials that Rémi Rabasa-Lhoret is conducting.
What is the office address of Rémi Rabasa-Lhoret?
The office of Rémi Rabasa-Lhoret is located at: Institut de recherches cliniques de Montréal, Montreal, Quebec H2W1R7 Canada. This is the address for their practice at the Institut de recherches cliniques de Montréal.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.